Recently, hibiscus acid was reported as a nutraceutical approach for the treatment of chronic myelogenous leukemia due to protein response observed by activation of eIF2α/ATF4 pathway that induced cell cycle arrest at G2/M phase and DNA fragmentation in leukemia K562 cells [31]. Here, ATF4 is linked to leukemia.